Updated mRNA COVID-19 Vaccines Targeted for Recent Subvariants

The Food and Drug Administration approved the updated mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna Sept. 11. These updated vaccines currently target circulating subvariants including XBB.1.5, EG.5 and FL.1.5.1, as well as BA.2.86, and provide improved protection against severe outcomes such as hospitalization and death.

The Centers for Disease Control and Prevention (CDC) convened its Advisory Committee on Immunization Practices Sept. 12, which issued recommendations about vaccination administration, dosing and scheduling. The final recommendation is that everyone six months of age and older should receive an updated COVID-19 vaccine this fall, ensuring it has been at least two months since receipt of the last COVID-19 vaccine dose.

Additional vaccination guidelines include:

  • Individuals six months – four years:
    • Complete a multi-dose initial series (two doses of Moderna or three doses of Pfizer) with at least one dose of the updated 2023-2024 vaccine.
    • If the initial series is already complete, 2023-2024 vaccine can be issued at least two months after receipt of last COVID-19 vaccine dose.
  • Individuals five years of age and older:
    • Regardless of prior vaccination, receive one dose of the updated 2023-2024 COVID-19 vaccine at least two months after receipt of last COVID-19 vaccine dose.
  • Individuals who are moderate or severely immunocompromised:
    • Complete a three-dose initial series with at least one dose of the updated 2023-2024 COVID-19 vaccine.
    • Individuals may receive one or more additional COVID-19 vaccine doses.

Additional details are forthcoming and will be provided in CDC’s Interim Clinical Considerations.

Per the CDC, COVID-19 and flu vaccines may be coadministered, which may be an effective strategy to ensure broad vaccination coverage for all eligible Michiganders.

The U.S. Government ended distribution of COVID-19 vaccines through the current ordering system Sept. 12.

Updated vaccines can now be ordered:

Please note that Bivalent mRNA (Pfizer-BioNTech or Moderna) COVID-19 vaccines are no longer authorized for use in the United States. It is recommended providers remove all bivalent mRNA COVID-19 vaccines from storage units and dispose of them immediately, in accordance with local, state and federal regulations.

More information can be found in the Michigan Department of Health & Human Services press release or by visiting the CDC website.

Members with questions may contact Kelsey Ostergren at the MHA.

Combating the Novel Coronavirus (COVID-19): Week of June 20

MHA Covid-19 update

MHA Covid-19 updateAs of June 22, there were 714 adults and 27 children in Michigan with confirmed or suspected cases of COVID-19, with new cases averaging 1,780 per day the previous week. Over 100 hospitalized adults were being cared for in intensive care units. According to the state’s vaccine tracker, 67.4% of Michigan residents had received at least one dose of a COVID-19 vaccine as of June 22.

The MHA continues to keep members apprised of pandemic-related developments affecting hospitals through email updates and the MHA Coronavirus webpage. Important updates are outlined below.

Children Ages Six Months Through Five Years Eligible for COVID-19 Vaccine

The Michigan Department of Health and Human Services (MDHHS) announced June 21 that all Michiganders ages six months and up are now eligible for a COVID-19 vaccine. The pediatric vaccine, which received emergency use authorization for this age group from the Food and Drug Administration, was recommended by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices June 18. The MHA released a media statement following the CDC recommendation, which makes 500,000 more Michigan children eligible for vaccination.

The MDHHS is recommending providers begin vaccinating children ages six months and older as soon as possible. The Moderna series is two doses given 28 days apart for ages six months through five years. For children six months of age through four years, the Pfizer series is three doses, with the first two given three weeks apart and the third dose administered at least eight weeks after the second dose. For ages five and older, the Pfizer series is two doses given 21 days apart.

In addition, the CDC has issued important updates to the Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. The MDHHS has provided an outline of the updates. The updates are outlined in the attached communication from MDHHS.

Questions about COVID-19 vaccines should be directed to Ruthanne Sudderth at the MHA.

Additional information on the COVID-19 pandemic is available to members on the MHA Community Site and the MHA COVID-19 webpage. Questions on COVID-19 and infectious disease response strategies may be directed to the MDHHS Community Health Emergency Coordination Center (CHECC).